Baseline characteristics as parameters of choice of first-line therapy in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study
S.E. Rebuzzi 1, A. Signori 2, G. Fornarini 3, M. Buffoni 4, S. Bracarda 5, R. Iacovelli 6, S. Chiellino 7, E. Fantinel 8, C. Messina 9, V. Conteduca 10, L. Bonomi 11, F. Vignani 12, F.M. Deppieri 13, B. Maiorano 14, C. Nasso 15
(1) Ospedale San Paolo, Medical Oncology Unit, Savona, Italy – Italy, (2) Departmentof Health Sciences Section of Biostatistics, Università degli Studi di Genova, Genova, Italy – Italy, (3) Medical Oncology Unit 1, IRCCS Ospedale Policlinico San Martino, Genova, Italy – Italy, (4) Oncology Department, Spedali Civili di Brescia, Brescia, Italy – Italy, (5) Oncology Department, Azienda Ospedaliera Santa Maria Terni, Terni, Italy – Italy, (6) MedicalOncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy – Italy, (7) Oncologia Medica, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy – Italy, (8) UOC Oncology Department, AOU Integrata di Verona – Ospedale Borgo Trento, Verona, Italy – Italy, (9) Oncology Department, Ospedale Civico (A.R.N.A.S.), Palermo, Italy – Italy, (10) MedicaIOncology Department, Università degli Studi di Foggia, Foggia, Italy – Italy, (11) OncoIogy department, ASST Papa Giovanni XXIII, Bergamo, Italy – Italy, (12) MedicaI Oncology, Azienda Ospedaliera Ordine Mauriziano, Presidio Umberto I, Torino, Italy, – Italy, (13) MedicaI Oncology, Ospedale deII’AngeIo – Mestre, Mestre, Italy – Italy, (14) Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS„ San Giovanni Rotondo, Italy – Italy, (15) Savona – Italy
Authors
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Fornarini, Martina Buffoni, Sergio Bracarda, Roberto Iacovelli, Silvia Chiellino, Emanuela Fantinel, Carlo Messina, Vincenza Conteduca, Lucia Bonomi, Francesca Vignani, Filippo Maria Deppieri, Brigida Maiorano, Cecilia Nasso, Emilia Cocorocchio, Nicolò Cavasin, Sebastiano Buti, Marco Maruzzo, Davide Bimbatti
Objective:
Despite many first-line therapeutic options in mRCC, no formal comparisons and no standard parameters are available to guide the treatment choice. The ongoing Meet-URO 33 study will recruit up to 80 Italian centres to answer many clinical unmet needs.
Methods:
The Meet-URO 33 study is a multicenter prospective/retrospective registry of a real-world mRCC population receiving first-line therapy from January 2021. As of April 2024, 421 pts from 25 Italian centers were assessed. We investigated which clinical/tumoral characteristics (age, ECOG PS, type/number of comorbidities, steroids, primary tumor surgery, histology, sarcomatoid features, type/number of metastases, IMDC and Meet-URO scores) influenced the choice among IO-IO, IO-TKI and TKI.
Results:
Overall, 263 pts (62.5%) received IO-TKI, 81 (19.2%) IO-IO and 77 (18.3%) TKI. At the univariate analysis, the IMDC and Meet-URO scores, age, bone/pancreatic metastases, high-dose steroids, renal/cardiac/hematological/metabolic/gastroenteric comorbidities and ≥2 comorbidities significantly correlated with the therapeutic choice (p<0.05). At the multivariate analyses, in the IO-IO vs IO-TKI comparison, a higher IMDC score and metabolic comorbidities correlated with IO-IO (p<0.001 and p=0.005), while the presence of bone metastases with IO-TKI (p=0.024); in the IO-IO vs TKI comparison, a higher IMDC score was associated with IO-IO (p<0.001) and a higher age with TKI (p=0.09); in the IO-TKI vs TKI comparison, a higher number of metastases correlated with IO-TKI (p=0.037) while a higher age, gastroenteric/renal comorbidities and ≥2 comorbidities with TKI (p<0.001, p=0.024, p=0.024 and p=0.046).
Conclusions:
The results of this preliminary data of the ongoing Meet-URO 33 study showed a real-world scenario of the current first-line setting in mRCC pts. Despite some well-known prognostic factors (e.g. ECOG PS, sarcomatoid features, lung/liver metastases) seems not be relevant parameters of therapeutic choice, others were confirmed to direct our therapeutic choices (IMDC score, bone metastases, number of metastases, age, comorbidities). These findings are food for thought for further analyses with a larger sample size.
Abstract Code: IUC20759-88